Opinion
Video
Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Dr Yehuda Handelsman on How DCRM 2.0 Guidelines Refine CRM Disease Management
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
Top 5 Most-Read Articles on Rare Blood Disorders in 2024
Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa
Further Refining the Myasthenia Gravis Continuum
ICYMI: Highlights From CHEST 2024